Easton Pharmaceuticals Announces It Has Engaged Online Marketing and Branding Specialists to Support the Firm's Updated Products, Branding and Website Launch; Provides Update on Its Medical Marijuana Initiatives

TORONTO, ONTARIO--(Marketwired - Mar 19, 2014) -  Easton Pharmaceuticals Inc. (OTC: EAPH), a specialty pharmaceutical company that owns, designs, develops, and markets an array of topically-delivered drugs and therapeutic / cosmetic healthcare products, today announces it has hired marketing and branding specialists to support the firms brand and online marketing awareness, as well as provide an update on its medical marijuana initiatives.

Easton Pharmaceuticals has recognized that its website, online marketing strategy and branding needed improving. As a result, Easton has engaged the services of a leading Toronto-based branding agency who have established itself in the industry with being able to assist companies such as Easton Pharmaceuticals to gain brand recognition while possessing strong sales and marketing skills to effectively promote the company's products and website awareness. The company utilizes some of the most proficient digital solutions managers for website development. Easton Pharmaceuticals has been in the process of revamping the company's website which is expected to be online no later than the beginning of next week which will also eventually allow the company's products to be purchased directly through its website. In addition, Easton is revamping its product line which includes packaging, naming of products, brochures and literature which will be showcased on the company's updated website, set to be unveiled in the next few days.

In other developments, Easton Pharmaceuticals, as previously stated by the company, is presently in the process of drafting and executing, through their respective attorneys, a final definitive agreement towards its Medical Marijuana Initiatives. The Company apologizes for the many delays, but most have not been in the control of the company. Easton has been in negotiations with various companies, some of which have been disclosed, which has now been narrowed down to a joint partnership for the intended acquisition of up to 3 companies and property who have applied for MMPR licenses for all of Canada, been granted an approval to build out what are considered very large facilities as mandated per MMPR regulations and have been growing Marijuana for current dispensaries including the supplying of Marijuana for Research & Development to various institutions. All of which have added to the complexity of the negotiations. Easton Pharmaceuticals believes its patented transdermal delivery system can one day in the near future be used to administer drugs for the treatment of various ailments and conditions utilizing certain agents derived from Marijuana. As stated, it is the company's full intention on utilizing its cash position towards an acceptable agreement to enter into what is believed to be the bourgeoning medical marijuana industry. 

About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company involved in various industries including medical marijuana who also owns, designs, develops, and markets topically-delivered drugs and therapeutic / cosmetic healthcare products, focused on cancer and other health issues related towards male and female sexual dysfunction, wound healing, pain, motion sickness, scar and stretch marks, cellulite, varicose veins and other conditions. The company's gel formulation is thought to be an innovative and unique transdermal delivery system. Easton Pharmaceuticals product "VIORRA", is an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity which is believed to have a positive effect on women's sexual desire and arousal, FSAD (Female Sexual Arousal Disorder) the world market for these female conditions are conservatively estimated to be in the billions. VIORRA is a topical, daily-use product classified by the FDA as containing Generally Recognized as Safe ingredients. 

For More Information Visit:

http://www.ashleybiomedical.com & http://www.eastonpharmaceuticalsinc.com

Safe Harbor

This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.